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a b s t r a c t 
Latent tuberculosis infection (LTBI) screening and preventive treatment is one of the components of the 
World Health Organization (WHO) End TB strategy, and particularly relevant for low tuberculosis (TB) 
incidence countries, i.e. less than 100 TB cases per million population. The Netherlands is such a low- 
incidence country with traditionally a strong emphasis on programmatic management of LTBI, e.g. exam- 
ining contacts of infectious TB patients by the public health services. Increasingly, curative services are 
involved in LTBI management of clinical risk groups. The country recently adopted a ﬁve-year strategic 
national plan recommending LTBI screening of high-risk migrants populations. A monitoring and evalu- 
ation system is already in place to measure programme performance and guide policy. Research on LTBI 
screening of migrants is on-going and results should inform future decisions in scaling-up this interven- 
tion. Several challenges remain for programmatic LTBI management, such as securing ﬁnancial resources 
and the right professional cadre for implementation; availability of screening tests and drugs; collecting 
additional data for monitoring and evaluation, in line with the WHO indicators for LTBI programmatic 
management; developing cultural-sensitive and client-centred education for migrants; reducing patient 
costs for LTBI screening and preventive treatment; and assessing cost-effectiveness and impact on TB 
epidemiology. 
© 2017 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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In 2014, the World Health Assembly adopted the World Health
Organization (WHO) post-2015 tuberculosis (TB) strategy [1] . The
End TB Strategy, as it is now called, is the third long-term strat-
egy of the WHO after TB was declared a public health emergency
in 1993 [2,3] . The End TB Strategy (2016–2035) has three pillars:
integrated, patient-centred care and prevention; bold policies and
supportive systems and intensiﬁed research and innovations. The
three pillars altogether are composed of ten components. It is for∗ Corresponding author at: KNCV Tuberculosis Foundation, P.O. Box 146, 2501 CC 
Den Haag, The Netherlands. 
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http://dx.doi.org/10.1016/j.jctube.2017.02.002 
2405-5794/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article uhe ﬁrst time that preventive treatment of persons with a latent TB
nfection (LTBI) at high risk for active TB is a component of a WHO
B strategy (under the ﬁrst pillar). 
In 2014, WHO and the European Respiratory Society (ERS) also
eveloped a framework for TB elimination in low-incidence coun-
ries [4,5] . One of the eight priority areas is screening for active TB
nd LTBI in TB contacts and selected high-risk groups, and provide
ppropriate treatment. The Framework also includes (new) deﬁ-
itions of low incidence, pre-elimination and elimination, i.e. less
han 100, 10 and 1 notiﬁed TB cases per 1 million population. The
etherlands is one of the 33 low-incidence countries and territo-
ies (with > 30 0,0 0 0 population) worldwide, with a TB notiﬁcation
ate of 50 per million population in 2015 ( Fig. 1 ) [6,7] . Program-
atic management of LTBI is supported by the WHO Guideline onnder the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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CPT Committee for Practical Tuberculosis Control 
EU European Union 
HIV Human Immunodeﬁciency Virus 
IGRA Interferon Gamma Release Assay 
LTBI Latent tuberculosis infection 
NTCP National Tuberculosis Control Plan 
NTR Netherlands TB Register 
PTB Pulmonary Tuberculosis 
TB Tuberculosis 
TNF Tumour Necrosis Factor 
TST Tuberculin Skin Test 
WHO World Health Organization 
his topic released in 2014 [8,9] , and the WHO Global Task Force
n LTBI initiated in 2015 [10] . 
The Global TB Programme of WHO, in collaboration with the
epublic of Korea’s Centers for Disease Control and Prevention
nd International Tuberculosis Research Center, organized on 27–
8 April 2016, in Seoul, Republic of Korea, a global consultation
n the management of LTBI to present and discuss challenges to,
pportunities for, and best practices on the programmatic man-
gement of LTBI, and to consider recommendations to facilitate itsFig. 1. Tuberculosis (TB) notiﬁcation rate in countries with a WHO estimated TBmplementation in both low- and high-burden countries [11] . The
etherlands was one of the countries sharing its experiences with
rogrammatic management of LTBI, and these are elaborated on in
his manuscript. 
he Netherlands and its health infrastructure 
The Netherlands is a member state of the European Union (EU).
n 2016, the population increased to more than 17 million inhab-
tants, of whom 19.6% were not born in the country. The country
s densely populated with 409 persons per km 2 (surface area is
1,543 km 2 ) [12] . The Netherlands is a high-income country and
mong the world’s top 20 in terms of gross domestic product per
apita [13,14] . 
The Dutch health care system includes about 80 0 0 general
ractitioners, 88 hospitals (including 8 university hospitals) and 25
unicipal Public Health Services (MPHS). Hospitals provide cura-
ive services to patients, mostly after referral by general practition-
rs, and MPHSs provide public health services, including infectious
isease prevention and control activities. The role and responsibil-
ty of municipalities and MPHSs is outlined in a Public Health Act. 
Citizens in the Netherlands are obliged to take a health insur-
nce. The health insurance covers costs of medical treatment, but
atients have to pay the ﬁrst amount of medical costs – excluding
osts for General Practitioner visits – incurred during a year (385 incidence < 10/10 0,0 0 0, (only countries with population > 30 0,0 0 0), 2015. 
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Fig. 2. Coverage of Municipal Public Health Services in The Netherlands. 
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i  Euro’s in 2016). TB and LTBI treatment costs are not exempted.
Children and adolescents < 18 years however are exempted from
this contribution to medical costs, including TB/LTBI diagnosis and
treatment. 
Tuberculosis control in the Netherlands 
TB control started as a private initiative of benevolent societies
in early 1900 s and these organizations were incorporated in the
MPHSs in the 1980 s. Currently, 23 MPHSs implement TB control
activities, while two MPHSs have outsourced these activities to a
larger MPHS ( Fig. 2 ). TB departments of MPHSs are staffed by pub-
lic health TB control physicians, specially trained for a combination
of public health and clinical TB responsibilities, who read chest
radiographs and diagnose and treat TB and LTBI patients, among
other tasks; specialized TB nurses who support patients, supervise
their medication and conduct contact investigation; and medical
technical assistants who perform tuberculin skin testing (TST), take
blood for interferon gamma release assays (IGRAs), make chest ra-
diographs and perform administrative tasks. The MPHSs conduct
radiographic screening of risk groups, such as immigrants, asylum
seekers and prisoners, and perform LTBI screening, e.g. in contact
investigation. 
Clinical specialists, mainly pulmonologists and infectious dis-
ease specialists, diagnose and treat TB (about 75–80% of all notiﬁed
patients) and LTBI patients in the curative sector. LTBI screeningnd preventive treatment has become an increasing part of these
ospitals specialists’ responsibilities due to an increase of immuno-
uppressed patients, e.g. patients with HIV, those starting medica-
ion such as Tumour Necrosis Factor (TNF)-alpha blocking therapy,
nd transplantation patients receiving immunosuppressive drugs.
n the context of a reducing TB caseload, with the potential of di-
inishing expertise, and the increased relevance of LTBI manage-
ent in the clinical setting, a training program was set up in 2011
or pulmonologists and infectious disease specialists to train them
n the function of hospital TB coordinator. 82% of all hospitals in
he Netherlands now have such a dedicated hospital TB coordina-
or. MPHS public health TB control physicians, TB nurses and hos-
ital TB coordinators work closely together. 
Two hospitals have facilities for long-term admission and spe-
ialized treatment of TB patients, so-called modern sanatoria. All
DR-TB patients and, on indication, clinically complex or socially
roblematic TB cases are admitted in these centres, as well as pa-
ients with a court order for mandatory isolation. 
pidemiology of tuberculosis in the Netherlands 
At the end of the 19th century, TB was the major killer disease
n Western countries [15] , with 0.25% of the population dying an-
G. de Vries et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 7 (2017) 40–48 43 
Fig. 3. Number and rate of tuberculosis notiﬁcation, The Netherlands, 1975–2015. 
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 ually of TB in the period 1866–1875 [16] . In the 1950 s, apart from
ortality registration, a morbidity notiﬁcation system was set up
or active TB. After the availability of an effective combination ther-
py, notiﬁcation rates declined until the mid-1980 s with about 8%
er year. Fig. 3 shows the upsurge of TB in the period 1985–1995,
redominantly as an effect of increased migration. The last twenty
ears, the TB notiﬁcation rate declined relatively steady, although
n 2015, it increased with 6%, mainly as a result of a high inﬂux
f asylum seekers in the Netherlands (867 patients, TB notiﬁcation
ate 51 per million in 2015) [6] . 
The number of TB patients born in the Netherlands declined
ver the last forty years and their stratiﬁed notiﬁcation rate al-
ost reached the pre-elimination level of 10 cases per 1 million
opulation. In 2015, 234 patients born in the Netherlands were re-
orted to the Netherlands TB Register (NTR), translating in an over-
ll notiﬁcation rate of 15 cases per million population, of whom
4.8% had one or both parents born in a foreign country. However,
he TB notiﬁcation rate for the population born in the Netherlands
or those younger than 65 years was 10 per million and for those
t least 65 years old 22 per million. It is expected that the de-
line in the older population will continue due to the cohort effect
17,18] . 
Among the foreign-born population the notiﬁcation rate is
uch higher (338 per million). Although the TB notiﬁcation rate
s highest in the ﬁrst years upon arrival in the Netherlands, the
ajority (58%) of foreign-born TB cases resided more than two
ears in the Netherlands at the time of diagnosis [6] . In a previ-
us study, 52% of the foreign-born patients with culture-conﬁrmed
B, who resided more than two years in the Netherlands, had a
nique DNA ﬁngerprint suggesting that even among TB patientsaving lived in the Netherlands for a longer time, at least half of
hem had a reactivation of a TB infection acquired in the country of
rigin [19] . 
ational strategic tuberculosis control plan 
The Ministry of Health commissioned the National Institute for
ublic Health and the Environment (RIVM) for the second time to
evelop a ﬁve-year National TB Control Plan (NTCP), together with
NCV Tuberculosis Foundation and other stakeholders. The previ-
us NTCP 2011–2015 focused on concentration and specialization
f TB control, laboratory and curative services due to the decline
f the number of TB cases, while maintaining quality services [20] .
he current NTCP 2016–2020 describes the effort s needed to re-
uce TB incidence in the Netherlands [21] , in line with the WHO
nd TB Strategy and the WHO European Region Tuberculosis Ac-
ion Plan 2016–2020 [1,22] . The target in the WHO European Re-
ion TB action plan to reduce TB incidence with 25% by 2020 was
dopted. A national target was set to also reduce in-country TB
ransmission with 25% over the next ﬁve years. The main new
ntervention to reach these targets is to screen new immigrants
nd asylum seekers for LTBI and provide preventive treatment to
hose infected. The following objectives/activities related to LTBI
re listed in the NTCP 2016–2020: 
1. The radiographic screening of newly arrived immigrants will be
gradually replaced or supplemented by LTBI screening, with pri-
ority for migrant children and immigrants from high-incidence
countries (TB incidence > 20 0/10 0,0 0 0). The implementation,
cost-effectiveness and im pact of LTBI screening is to be eval-
44 G. de Vries et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 7 (2017) 40–48 
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a  uated in 2018, and thereafter a decision is made whether LTBI
screening can be extended to other immigrants. 
2. By 2018, all hospitals should have an approved protocol for the
diagnosis and treatment of TB and LTBI in clinical risk groups.
Data of hospital LTBI screening policy needs to be collected and
analysed at national level. 
3. Criteria should be deﬁned for supervision of TB and LTBI pa-
tients, including the new target group for LTBI screening, i.e.
recently arrived immigrants. Patients are explicitly involved in
deﬁning these criteria. The criteria need to be evaluated two
years after implementation, again with input of (former) pa-
tients. 
Policy and practices of latent tuberculosis infection 
management 
TB guidelines are developed in the Netherlands by a multi-
disciplinary Committee for Practical TB Control (CPT). The guide-
lines are regularly evaluated and revised, and compiled in a yearly
updated TB Manual [23] . LTBI diagnosis is mainly done by a two-
step approach, i.e. an initial TST followed by an IGRA if TST
≥5 mm. Both tests are recommended simultaneously for LTBI di-
agnosis in clinical risk groups (HIV patients, patients starting TNF-
alpha blocking medication and candidate organ transplant pa-
tients) to increase sensitivity. LTBI is treated with 3 months’ isoni-
azid/rifampicin (3HR), or 6 months’ isoniazid (6H) or 4 months’ ri-
fampicin (4R) [8,9,24–28] . Persons initiating LTBI treatment should
be screened for potential risk factors for possible adverse effects,
e.g. transaminases in persons with a history of liver disease, alco-
hol abuse, HIV infection, older than 35 years, pregnancy and dur-
ing the ﬁrst three months of post-partum. Patients on preventive
treatment should be evaluated every month for adverse effects and
treatment adherence. Preventive treatment is extended to 4HR and
9H in patients with immunosuppressive disorders or starting im-
munosuppressive medication and those with pulmonary ﬁbrotic le-
sions. For the latter condition, it is crucial that active TB is ruled
out [29] , which is deﬁned in the Netherlands by unaltered radio-
logical ﬁndings over a period of three months, absence of symp-
toms during this period and negative results of sputum culture for
Mycobacterium tuberculosis complex, or, based on the clinician’s de-
cision, on material obtained by sputum induction or bronchoscopy
[30] . 
LTBI screening is recommended for contacts exposed to bac-
teriological (smear-positive and/or culture-conﬁrmed) pulmonary
TB, clinical risk groups, occupational risk groups (pre-employment
screening of health care workers with previous high-risk for TB
exposure and periodically, those with increased risk during work)
and travellers returning from high-incidence countries. In Decem-
ber 2015, the CPT recommended to screen migrants < 18 years
(also) for LTBI, which is now gradually implemented countrywide.
Illicit drug users and homeless persons are not (yet) included as
target groups for LTBI screening in national guidelines, but this
is being piloted by the MPHS Amsterdam, and hence radiographic
screening for those uninfected or treated for LTBI is discontinued.
Since this pilot started on 1 April 2015, until 30 June 2016, 160
persons were screened for LTBI, 22 (14%) diagnosed with LTBI, 16
(73%) started preventive treatment and 14 (88%) completed the
treatment. 
Box 1 provides a practice of LTBI management in one of the
hospitals in the Netherlands, including agreement on screening
pathways, responsibilities for treatment and reporting and record-
ing of the results. Similar initiatives with dedicated clinics for LTBI
examination and preventive treatment of clinical risk groups are
developed in other hospitals. ox 1 . Practice of latent tuberculosis infection management in a
ospital in The Netherlands. 
Pulmonologists, rheumatologists, dermatologists and gas- 
troenterologists of the Gelderse Vallei Hospital, a 600-bed hos- 
pital in the central-eastern part of the Netherlands, agreed in 
2013 that all patients initiating TNF-alpha blocking medication 
should be tested for LTBI and TB. Patients were first screened 
with an IGRA and a chest radiograph, and then referred to the 
pulmonology department for a TST and to complete a ques- 
tionnaire with clinical risk factors for TB and factors influenc- 
ing test results. Based on all test results, the pulmonologist 
decides whether the patient can start TNF-alpha blocking med- 
ication, or whether the patient first should start treatment for 
LTBI (or TB). When preventive treatment is started, both spe- 
cialists agree on the start of TNF-alpha blocking medication, 
which generally is delayed until the patient has been on treat- 
ment for a minimum of two months. 
Since November 2015, also pre-transplantation patients, 
mainly for kidney transplantation, follow the same work-up. 
Newly diagnosed HIV patients are referred to another hospital 
for case management, including TB/LTBI screening. 
Pulmonologists treat all LTBI patients and report the cases 
to the MPHS for registering in the NTR. In the years 2013–2015, 
annually 80, 81 and 83 patients were screened for LTBI, and 88 
patients in 2016 (until 30 September 2016). In 2015 and 2016, 
10 patients (5.8%) were notified with LTBI to the MPHS in the 
area, and started preventive treatment. 
onitoring and evaluation of latent tuberculosis infection 
LTBI is reported on a voluntary basis to the NTR. This register
tarted in 1993 as a paper case-based registry for TB and LTBI cases
nd was integrated in 2005 into a central web-based register for
nfectious disease surveillance [31] . At that time, also a new case
eﬁnition for LTBI cases to be reported, was agreed upon, based on
he eligibility for preventive treatment according to national guide-
ines [32] . This includes individuals with a positive LTBI test with
) a high likelihood of recent infection ( < 2 years ago), 2) pul-
onary ﬁbrotic lesions consistent with active TB in the past and
ithout adequate treatment, 3) severe immunosuppressive disor-
ers (e.g. HIV infection), and 4) planned immunosuppressive ther-
py (pre-TNF-alpha blocking therapy/pre-organ transplantation). 
Characteristics of notiﬁed TB and LTBI cases are annually de-
cribed in the TB Surveillance Report [6] . In 2015, 1433 LTBI
ases were reported to the NTR (8.5 per 10 0,0 0 0 persons),
1% were identiﬁed through contact investigation, 20% by pre-
mployment or pre-travel screening and 14% by screening of indi-
iduals with immunosuppressive disorders or starting immunosup-
ressive treatment ( Table 1 ). 1128 (79%) started preventive treat-
ent, 14% of cases were followed-up for two years with chest ra-
iography and in 7% of cases the LTBI management policy was not
et known. As with TB cohort analysis, LTBI treatment results of
he previous year are also reported in the TB Surveillance Report.
f the 1013 LTBI cases that started preventive treatment in 2014,
9% completed treatment, 5% defaulted, and 4% discontinued treat-
ent due to side effects. Information of TB and LTBI cases and case
anagement is electronically available at www.tbc-online.nl . 
Results of 21 years’ programmatic management of LTBI in the
etherlands (1993–2013) were recently published [32] . In that pe-
iod, 37,729 persons were registered with LTBI; 77% started preven-
ive treatment and 82% of these cases completed treatment. Two-
hirds of the notiﬁed LTBI cases were detected through contact in-
estigation. Preventive treatment initiation was highest in groups
ore likely to progress to active TB, such as TB contacts, children
nd immunosuppressed persons. Children and immunosuppressed
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Table 1 
Latent tuberculosis infection indicators in The Netherlands, 2015. 
Target group for LTBI screening in the 
Netherlands 
Number 
eligible for LTBI 
screening 
Number 
screened for 
LTBI 
Screening 
coverage 
Number LTBI 
cases diagnosed 
and reported to 
NTR 
Number cases 
that initiated 
LTBI treatment 
LTBI treatment 
coverage 
Number 
completed LTBI 
treatment 
(2014) 
LTBI completion 
rate (2014) 
Number with 
active TB 
reported to 
NTR 
TB incidence 
among target group 
(per 10 0,0 0 0) 
All contacts of TB patients ∗ ∗ ∗ 867 679 78% 505/575 88% 65 
People living with HIV 865 ‡ Unknown – 3 3 100% 4/4 100% 36 
Patients initiating / on TNF-alpha 
blocking treatment 
Unknown Unknown – 192 ∗∗ 177 ∗∗ 92% 151/169 ∗∗ 89% 14 
Patients preparing for (or with) organ 
or hematologic transplantation 
Unknown Unknown – 5 
Health care workers Unknown Unknown – 21 17 81% 27/29 93% 6 
Travelers Unknown Unknown – 22 18 82% 20/20 100% 
Others ∗∗∗ Unknown Unknown – 328 234 79% 194/216 90% 
Total Unknown Unknown – 1433 1128 79% 901/1013 89% 
Note: There is no policy in the Netherlands to screen patients with renal insuﬃciency/ dialysis or with silicosis for LTBI. 
LTBI: latent tuberculosis infection; NTR: Netherlands Tuberculosis Register; TB: tuberculosis. 
∗ Data is available of the number of contacts eligible for TB examination in source tracing and contact investigation (n = 7162) related to a TB patient diagnosed in 2014, the number of contacts actually screened for LTBI 
(n = 5446) and the screening coverage (76%). The dataset allows a breakdown in intensity of contacts, i.e. household and close contacts, but not (yet) for age group, such as children. 
∗∗ LTBI screening data in the NTR has been combined for patients initiating TNF-alpha blocking therapy and preparing for transplantation. 
∗∗∗ Others: mainly pre-employment, pre-travel and other low-risk LTBI screening. 
‡ E stimated number of newly diagnosed patients with HIV in 2015 in the Netherlands [55] . Immigrants from TB high-incidence countries and HIV patients at increased risk for TB due to travel or other exposure (contacts of 
TB patients) are prioritised in the Netherlands for LTBI screeing [56] . 
46 G. de Vries et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 7 (2017) 40–48 
Table 2 
Contacts screened for and diagnosed with latent tuberculosis infection in contact investigations in The Netherlands, 2006–2010. 
Smear-positive pulmonary PTB Smear-negative culture-positive pulmonary PTB 
Number screened 
for LTBI (n) 
Number with 
LTBI (n) 
Proportion 
infected (%) 
Number screened 
for LTBI (n) 
Number with 
LTBI (n) 
Proportion 
infected (%) 
1st Ring 10,108 1359 13.4 2512 184 7.3 
2nd Ring 14,651 878 6.0 2523 114 4.5 
3rd Ring 11,233 350 3.1 918 33 3.6 
Total 35,992 2587 7.2 5954 331 5.6 
LTBI = latent tuberculosis infection; PTB = pulmonary tuberculosis. 
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 persons were also more likely to complete preventive treatment, as
were individuals treated with the rifampicin or isoniazid/rifampicin
regimens. Male gender, age younger than 15 years and rifampicin
containing short regimens were associated with a lower risk to
discontinue the treatment due to serious adverse events. A study,
following-up 14,231 persons notiﬁed with LTBI (2005–2013) in the
Netherlands, found that 134 (0.9%) were notiﬁed with active TB
[33] . Effect of preventive treatment reduced TB incidence among
TB contacts in the ﬁrst two years after diagnosis at least 2-fold. 
Recently, WHO published a list of core global, core national and
optional indicators to monitor and evaluate LTBI management [7] .
We applied this framework to the Dutch LTBI surveillance sys-
tem ( Table 1 ). The number of people eligible for screening and
the number actually screened is unknown for most of the target
groups for LTBI screening. Persons with clinical risk factors are
mainly screened in hospitals and information on diagnosed LTBI
cases and management is incomplete, although there is an increase
of reporting, mainly those with immunosuppressive disorders or
candidates for immunosuppressive therapy [6] . 
Contact investigation is included in the list of WHO LTBI indi-
cators. Source tracing and contact investigation has been evaluated
systematically in the Netherlands for the years 2006–2010 [34] . In
this period, contact investigations were done around 1062 smear-
positive pulmonary TB (PTB) patients and in 613 smear-negative
culture-positive PTB patients, according to the stone-in-the-pond
principle [35] . This yielded 2587 and 331 LTBI cases respectively
( Table 2 ), in addition to 208 and 47 secondary active TB cases re-
spectively (data not shown). The yield of contact investigations for
2011–2015 will be evaluated in 2017. 
Research on latent tuberculosis infection 
Over the last decade, the Netherlands Organization for Research
and Development (ZonMw) ﬁnanced three large research (PhD)
projects addressing the prevention of LTBI among the immigrant
population. In the PREDICT studies (20 05–20 08), the predictive
value of TST and IGRA in immigrant contacts was studied [36–38] .
In the TB PERSPECTIVE studies (2009–2012), the role of TST and
IGRA in screening immigrants in contact investigation or at arrival
in the Netherlands was subject of research [39–42] , as well as the
cost-effectiveness of TB and LTBI screening and modelling its im-
pact. In 2013, using remaining budget, we investigated the feasi-
bility of LTBI screening of immigrants arriving in the country. In
total, 726 immigrants younger than 35 years were tested, either
with TST followed by IGRA if TST ≥5 mm, or with IGRA only. Of
those, 88 (12%) persons were diagnosed with LTBI, and one person
was diagnosed with active TB. 73 persons were offered preventive
treatment; 34/73 (47%) initiated preventive treatment of whom 26
(76%) completed the treatment. 
Recently, ZonMw ﬁnanced the TB ENDPoint project (2016–2019)
which addresses the perceived barriers for implementation of LTBI
screening and preventive treatment among immigrants from coun-
tries with a TB incidence > 50/10 0.0 0 0. So far, 583 immigrants
have been enrolled for LTBI screening, enrolment of 800 asylumeekers for LTBI screening is currently taking place, followed by
00 immigrants with a high-risk for TB will be enrolled in a com-
unity screening project. After completion of the three pilots, the
roject will also assess the cost-effectiveness of the intervention
nder optimized conditions. The data from this research will be
he basis for a business case document, which will guide policy
akers in the decision whether or not to extend LTBI screening to
ther immigrants. 
hallenges to scale up latent tuberculosis infection 
anagement 
The Netherlands, with already a long history of LTBI screening
nd treatment, faces several challenges to scale up LTBI program-
atic management, such as: 
1) Political commitment, with maintaining and adapting the pub-
lic health infrastructure for TB control. The decline of the num-
ber of TB cases in this century also caused a decrease in ﬁnan-
cial and human resources. The current emphasis on program-
matic management of LTBI requires an adaptation of the sys-
tem, with securing adequate ﬁnancial resources and the right
human resource cadre to implement it. TB nurses and nurse
physician assistants can play a stronger role in LTBI manage-
ment. 
2) Availability of LTBI screening tests and drugs. The main supplier
of tuberculin in the EU had irregular supplies over the last years
and recently stopped to supply this diagnostic, creating short-
ages in EU countries [43] . IGRA tests are costly for scaling up
LTBI screening. New screening tests are at the horizon [44] , but
better tests/biomarkers to predict disease are urgently needed.
The pharmaceutical company manufacturing isoniazid in the
Netherlands stopped producing the drug after the Fukoshima
nuclear disaster, from which area the substance for drug devel-
opment was procured, and only recently restarted the isoniazid
drug production. Rifapentine, already registered with the Drug
and Food Administration in the United States since 2014, is not
yet available on the European market. The drug is promising
since it will only require patients to take 12 (weekly) doses of
LTBI treatment [45] . KNCV Tuberculosis Foundation, European
organisations, including patient organisations, and individuals
from 20 different European countries signed a letter request-
ing Sanoﬁ, the company producing rifapentine, to take all steps
to register the drug in Europe ( www.kncvtbc.org/rifapentine ). 
3) Monitoring and evaluation of LTBI management. Although LTBI
cases are already reported for almost 25 years in the Nether-
lands, there is underreporting of LTBI cases, especially those di-
agnosed in the clinical settings. Legislation, making LTBI a noti-
ﬁable condition, could help to increase reporting coverage, as is
the case in Japan [7] . Another major challenge is to measure or
estimate the number of persons eligible for LTBI screening and
the number actually screened. We will work towards improving
this in Europe as part of a recently started European Commis-
sion co-ﬁnanced project, E-DETECT TB [46] , which among oth-
ers aims to collect and analyse TB and LTBI migrant screening
G. de Vries et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 7 (2017) 40–48 47 
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 data in Italy, The Netherlands, Sweden and the United Kingdom.
The project will invite other interested European countries to
collaborate. 
4) General public and client education. LTBI is a concept that
is badly understood outside the TB professional community.
Awareness rising campaigns are needed to successfully intro-
duce programmatic LTBI screening of migrants and tailored,
cultural-sensitive client-centred education is necessary to en-
sure adherence to, and completion of, LTBI treatment [47] . 
5) Patient cost. The Dutch health insurance system is not support-
ive for successful programmatic management of LTBI, because
patients above 18 years have to pay the initial cost of health
consumption. Thus, many patients may end-up paying the full
cost of LTBI screening and treatment up to 385 Euro’s. The issue
has been raised to the Minister of Health, but did not lead to an
exemption for TB or LTBI patients. KNCV Tuberculosis Founda-
tion will collect case reports of impediments to access to care,
analyse these and report on the barriers [21] . 
6) Cost effectiveness and impact of programmatic management of
LTBI. Several studies showed that LTBI screening and preven-
tive treatment of migrants is cost-effective, but that it depends
on the TB incidence in the country of origin, methodology and
models [48–51] . Obviously, when introducing LTBI screening of
migrants, high-risk populations should be prioritized [50,52] .
The European Centre for Disease Prevention and Control (ECDC)
embarked on a project to provide EU and European Economic
Area (EEA) Member States and candidate countries with scien-
tiﬁc advice and guidance on programmatic LTBI Control, which
includes mathematical modelling and cost-effectiveness studies
[47] . This work will contribute towards a guidance document
that elaborates on the available options when considering pro-
grammatic LTBI control in the EU/EEA. 
onclusion 
This manuscript describes elements of programmatic manage-
ent of LTBI in a low-incidence country. Once countries reach this
ow-incidence phase, more emphasis on LTBI screening of high-
isk groups is needed to move towards elimination [4,53,54] . In the
etherlands, with 73% of the TB patients in the foreign-born pop-
lation, (newly arrived) migrants, including asylum seekers, from
igh-incidence countries are a relevant population to offer LTBI
creening [52] . Contacts of pulmonary TB patients and clinical risk
roups with a high risk of developing active TB, are also well-
dentiﬁable and need to be targeted for LTBI screening. The LTBI
creening policy of risk groups needs to be regularly updated based
n scientiﬁc evidence and evaluation of program performance, for
hich a monitoring and evaluation system is essential. 
Programmatic implementation of LTBI is highly context- and
ountry-speciﬁc [10,47] . The Netherlands has an excellent network
f public health and curative TB services with a long history of
ollaboration, which is now getting more directed towards LTBI
creening and TB elimination. Despite these supporting conditions,
everal challenges and threads remain, such as the availability of
iagnostic tests and drugs, the risk of losing adequate human re-
ources, strengthening monitoring and evaluation, health insur-
nce arrangements not supportive of scaling up programmatic LTBI
creening and uncertainties about cost-effectiveness and impact.
ow-incidence countries can pave the way towards elimination, but
o reach the goals set by the world to reduce global TB incidence
o 100 per million in 2035, investment in international TB control
nd the development of new tools is highly needed, which will
lso beneﬁt low-incidence countries receiving migrants from high-
urden countries. unding 
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